Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases

Anticancer Research

Volumn 32, Issue 12, 2012, Pages 5211-5220

  Kischel, Philippe ^a   Bellahcene, Akeila ^a   Deux, Blandine ^b   Lamour, Virginie ^a   Dobson, Rowan ^a   De Pauw, Edwin ^a   Clezardin, Philippe ^b   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

B02 cells; Bone metastasis; Breast tumor; Cancer cells; MDA MB 231; Membrane proteins; Osteotropism

Indexed keywords

CD9 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION; VISCERAL METASTASIS;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD9; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84872589533     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
2. Galasko CS: Skeletal metastases. Clin Orthop Relat Res pp. 18-30, 1986.
3. Coleman RE: Skeletal complications of malignancy. Cancer 80: 1588-1594, 1997.
4. Kischel P, Guillonneau F, Dumont B, Bellahcene A, Stresing V, Clezardin P, De Pauw EA and Castronovo V: Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia 10: 1014- 1020, 2008.
5. Berditchevski F: Complexes of tetraspanins with integrins: More than meets the eye. J Cell Sci 114: 4143-4151, 2001.
6. Levy S and Shoham T: Protein-protein interactions in the tetraspanin web. Physiology 20: 218-224, 2005.
7. Ikeyama S, Koyama M, Yamaoko M, Sasada R and Miyake M: Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. J Exp Med 177: 1231-1237, 1993.
8. Ishii M, Iwai K, Koike M, Ohshima S, Kudo-Tanaka E, Ishii T, Mima T, Katada Y, Miyatake K, Uchiyama Y and Saeki Y: RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J Bone Miner Res 21: 965-976, 2006.
9. Huang CI, Kohno N, Ogawa E, Adachi M, Taki T and Miyake M: Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 153: 973-983, 1998.
10. Miyake M, Nakano K, Itoi SI, Koh T and Taki T: Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56: 1244-1249, 1996.
11. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M and Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 56: 1751-1755, 1996.
12. Higashiyama M, Doi O, Kodama K, Yokouchi H, Adachi M, Huang CL, Taki T, Kasugai T, Ishiguro S, Nakamori S and Miyake M: Immunohistochemically detected expression of motility-related protein-1 (MRP-1/CD9) in lung adenocarcinoma and its relation to prognosis. Int J Cancer 74: 205-211, 1997.
13. Miyamoto S, Maruyama A, Okugawa K, Akazawa K, Baba H, Maehara Y and Mekada E: Loss of motility-related protein 1 (MRP1/CD9) and integrin α3 expression in endometrial cancers. Cancer 92: 542-548, 2001.
14. Sho M, Adachi M, Taki T, Hashida H, Konishi T, Huang CL, Ikeda N, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H and Miyake M: Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 79: 509-516, 1998.
15. Hashida H, Takabayashi A, Tokuhara T, Taki T, Kondo K, Kohno N, Yamaoka Y and Miyake M: Integrin alpha3 expression as a prognostic factor in colon cancer: Association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 97: 518-525, 2002.
16. Erovic BM, Pammer J, Hollemann D, Woegerbauer M, Geleff S, Fischer MB, Burian M, Frommlet F and Neuchrist C: Motility-related protein-1/CD9 expression in head and neck squamous cell carcinoma. Head Neck 25: 848-857, 2003.
17. Yau JC, Dabbagh LK, Formenti KS, Coupland RW, Burns BF and Shaw AR: Expression of transmembrane 4 superfamily member, CD9, is related to improved progression-free survival in patients with diffuse non-Hodgkin's lymphoma. Oncol Rep 5: 1507-1511, 1998.
18. Si Z and Hersey P: Expression of the neuroglandular antigen and analogues in melanoma. CD9 expression appears inversely related to metastatic potential of melanoma. Int J Cancer 54: 37-43, 1993.
19. Uchida S, Shimada Y, Watanabe G, Li ZG, Hong T, Miyake M and Imamura M: Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer 79: 1168-1173, 1999.
20. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
21. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R: A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486-1495, 2001.
22. Peyruchaud O, Winding B, Pecheur I, Serre CM, Delmas P and Clezardin P: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 16: 2027-2034, 2001.
23. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, Margue C, Cohen-Solal M, Buffet A, Kieffer N and Clezardin P: Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16: 1266-1268, 2002.
24. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581, 1994.
25. Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD and Keller ET: Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 47: 212-221, 2001.
26. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Leval J and Castronovo V: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90: 1000-1008, 1998.
27. Daubiné F, Le Gall C, Gasser J, Green J and Clézardin P: Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99: 322-330, 2007.
28. Auerbach R, Lu WC, Pardon E, Gumkowski F, Kaminska G and Kaminski M: Specificity of adhesion between murine tumor cells and capillary endothelium: An in vitro correlate of preferential metastasis in vivo. Cancer Res 47: 1492-1496, 1987.
29. Ruoslahti E and Rajotte D: An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 18: 813-827, 2000.
30. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
31. Rabilloud T: Membrane proteins ride shotgun. Nat Biotechnol 21: 508-510, 2003.
32. Hopkins AL and Groom CR: The druggable genome. Nat Rev Drug Discov 1: 727-730, 2002.
33. Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P and Castronovo V: Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat 101: 135-148, 2007.
34. Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A and Pandey A: Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics 5: 157-171, 2006.
35. Jamil F, Peston D and Shousha S: CD9 immunohistochemical staining of breast carcinoma: Unlikely to provide useful prognostic information for routine use. Histopathology 39: 572-577, 2001.
36. Kubista B, Erovic BM, Klinger H, Sulzbacher I and Trieb K: CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett 209: 105-110, 2004.
37. Longo N, Yanez-Mo M, Mittelbrunn M, de la Rosa G, Munoz ML, Sanchez-Madrid F and Sanchez-Mateos P: Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 98: 3717-3726, 2001.
38. Sauer G, Windisch J, Kurzeder C, Heilmann V, Kreienberg R and Deissler H: Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res 9: 6426-6431, 2003.
39. Leung KT, Chan KYY, Ng PC, Lau TK, Chiu WM, Tsang KS, Li CK, Kong CKL and Li K: The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood 117: 1840-1850, 2011.
40. De Bruyne E, Andersen TL, De Raeve H, Van Valckenborgh E, Caers J, Van Camp B, Delaisse JM, Van Riet I and Vanderkerken K: Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients. Leukemia 20: 1870-1879, 2006.
41. Hori H, Yano S, Koufuji K, Takeda J and Shirouzu K: CD9 expression in gastric cancer and its significance. J Surg Res 117: 208-215, 2004.
42. Zoller M: Tetraspanins: Push and pull in suppressing and promoting metastasis. Nat Rev Cancer 9: 40-55, 2009.
43. Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK and Anderson RL: Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res 8: R20, 2006.
44. Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clement-Lacroix P and Clezardin P: Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67: 5821-5830, 2007.